Intellia Therapeutics had its Relative Strength (RS) Rating upgraded from 65 to 75 Tuesday — a welcome improvement, but still shy of the 80 or better score you look for.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves. See if Intellia Therapeutics can continue to show renewed price strength and hit that benchmark.
While Intellia Therapeutics is not near a proper buy zone right now, see if it is able to form and break out of a proper consolidation.
Intellia Therapeutics reported 0% EPS growth in the latest quarterly report. Sales gains came in at 105%.
Intellia Therapeutics holds the No. 222 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
